SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)
Meridian Medical Technologies, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.10 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
589658103
--------------------------------------------------------------------------------
(CUSIP Number)
Robert G. Foster, 4 Milk Street, Portland, ME 04101 (207) 780-0904
--------------------------------------------------------------------------------
(Name, Address, Telephone Number of Persons Authorized to Receive Notices and
Communications)
April 1, 2002
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
Page 1 of Pages
--------------------------------------------------------------------------------
CUSIP No. 13D Page of Pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON
Robert G. Foster
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not Applicable
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS [ ]
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION United States
--------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH 62,142
------------------------------------------------
8 SHARED VOTING POWER
63,341
------------------------------------------------
9 SOLE DISPOSITIVE POWER
62,142
------------------------------------------------
10 SHARED DISPOSITIVE POWER
63,341
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
125,483
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.82%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
Schedule 13D Robert G. Foster
ITEM 2. IDENTITY AND BACKGROUND
The reporting person's name is Robert G. Foster, a U.S. citizen. The
reporting person is President and principal stockholder of Commonwealth
BioVentures, Inc. ("CBI"), a Massachusetts corporation and general partner of
BioVenture Partners Limited Partnership ("BPLP"), a Delaware limited
partnership, which is the general partner of two Delaware limited partnerships,
Commonwealth BioVentures IV Limited Partnership, a Delaware limited partnership
("Fund IV"), and Commonwealth BioVentures V Limited Partnership, a Delaware
limited partnership ("Fund V"), both of which are venture capital funds. The
business address for the reporting person and the entities identified above is 4
Milk Street, Portland, ME 04101.
During the last five years, none of the entities identified in the
paragraph above or the reporting person have been (i) convicted in a criminal
proceeding (excluding traffic violations and similar misdemeanors) or (ii) a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding has been or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
The number of shares of common stock of the Issuer which the reporting
person may be deemed to beneficially own is 125,483 (the "Shares"), which
represents approximately 2.82% of the Issuer's reported outstanding shares of
common stock as of February 28, 2002. 56,800 of the Shares represent Shares
which the reporting person may be deemed to have the right to acquire within 60
days. The reporting person has the sole power to vote and the sole power to
dispose of 62,142 of the Shares. By virtue of the relationships described in
Item 2 above among the reporting person, Fund IV, Fund V, BVLP, and CBI, the
reporting person shares the power to vote and dispose of (i) 10,484 of the
Shares held in the name of Fund IV with Fund IV, BVLP and CBI, (ii) 36,297 of
the Shares held in the name of Fund V with Fund V, BVLP and CBI and (iii) 1,490
of the Shares held in BVLP's name with BVLP and CBI. Additionally, the reporting
person shares voting and dispositive power with respect to 15,070 shares of the
Issuer's common stock held jointly by the reporting person and his former
spouse. The reporting person ceased to be a beneficial owner of more than 5% of
the Issuer's common stock on April 1, 2002 as a result of the transaction
described in the paragraph below.
Fund V, a venture fund, is in its last year of existence and has commenced
liquidating fund investments in contemplation of its termination and winding up
of its business. On April 1, 2002, Fund V distributed to its limited partners an
aggregate of 150,000 shares of the Issuer's common stock registered in Fund V's
name in accordance with the terms of Fund V's limited partnership agreement (the
"Distribution"). The Distribution was effected solely as part of the reporting
person's investment liquidation process and was not influenced by or otherwise
based upon the reporting person's evaluation of the Issuer's current or
anticipated business, financial, or stock price performance.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete, and correct.
April 2, 2002 /s/ Robert G. Foster
------------- ---------------------
Robert G. Foster